Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.48 |
| ▸ | FABP7 | O15540 | 2/20 | 0.48 |
| ▸ | CASP3 | P42574 | 3/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL119579 | 1.00 | KMT2A (0.48) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL29397325 | 1.00 | KMT2A (0.48) | KMT2AFABP5FABP7CASP3EPHX2 | |
| Water SCHEMBL21056515 | 0.99 | KMT2A (0.47) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL29861643 | 0.95 | KMT2A (0.44) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL30905364 | 0.95 | KMT2A (0.44) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL29299774 | 0.95 | KMT2A (0.44) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL31317449 | 0.95 | KMT2A (0.44) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL31584391 | 0.95 | KMT2A (0.44) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL31317420 | 0.95 | KMT2A (0.44) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL25821923 | 0.95 | KMT2A (0.44) | KMT2AFABP5FABP7CASP3EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250353875-A1 | PEPTIDE SYNTHESIS METHOD FOR SUPPRESSING DEFECT CAUSED BY DIKETOPIPERAZINE FORMATION | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2025-11-20 | — | — | US | disclosed |
| US-20250332300-A1 | HER2 TARGETING CYCLIC PEPTIDES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2025-10-30 | — | — | US | disclosed |
| EP-4631955-A1 | PURIFICATION METHOD AND PRODUCTION METHOD OF CYCLIC PEPTIDE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-10-15 | — | — | EP | disclosed |
| US-20250302912-A1 | COMPOSITION INCLUDING PEPTIDE COMPOUND AND SURFACTANT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-10-02 | — | — | US | disclosed |
| US-12410212-B2 | Cyclic compound having selective KRAS inhibitory effect on HRAS and NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-09 | — | — | US | disclosed |
| US-12404299-B2 | Method for producing peptide compound comprising highly sterically hindered amino acid | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-02 | — | — | US | disclosed |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-07-29 | — | — | US | disclosed |
| EP-4166133-B1 | COMPOSITION CONTAINING PEPTIDE COMPOUND AND SURFACTANT | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2025-07-23 | — | — | EP | disclosed |
| US-20250230193-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2025-07-17 | — | — | US | disclosed |
| US-20250186542-A1 | COMPOSITION CONTAINING PEPTIDE COMPOUND FOR USE WITH SURFACTANT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-06-12 | — | — | US | disclosed |
| CN-116981672-A | Macrocyclic compounds as CFTR modulators | 爱杜西亚药品有限公司 | 2023-10-31 | — | — | CN | disclosed |
| EP-4237008-A2 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | Elucida Oncology, Inc. (US) | 2023-09-06 | — | — | EP | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| US-20230096766-A1 | AMINO ACID HAVING FUNCTIONAL GROUP CAPABLE OF INTERMOLECULAR HYDROGEN BONDING, PEPTIDE COMPOUND CONTAINING SAME AND METHOD FOR PRODUCTION THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-03-30 | — | — | US | disclosed |
| US-20230026641-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND COMPRISING HIGHLY STERICALLY HINDERED AMINO ACID | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-01-26 | — | — | US | disclosed |
| CN-115467029-A | Chemical ring closure construction method of cyclic compound library and cyclic compound library | 亚飞（上海）生物医药科技有限公司 | 2022-12-13 | — | — | CN | disclosed |
| WO-2022234867-A1 | SULFONAMIDE HAVING MMP 7-INHIBITING ACTION | 大正製薬株式会社 | 2022-11-10 | — | — | WO | disclosed |
| WO-2022232411-A2 | ANTISENSE OLIGONUCLEOTIDES AND THEIR USE FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | Eisai R&D Mangement Co., Ltd. (JP) | 2022-11-03 | — | — | WO | disclosed |
| EP-4056580-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND COMPRISING HIGHLY STERICALLY HINDERED AMINO ACID | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2022-09-14 | — | — | EP | disclosed |
| WO-2022093800-A2 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | ELUCIDA ONCOLOGY, INC. (US) | 2022-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | KMT2A 3145/4885FABP5 4094/4885FABP7 4602/4885 |
| US-12410212-B2 | Cyclic compound having selective KRAS inhibitory effect on HRAS and NRAS | KRAS, HRAS, NRAS | KMT2A 1250/4885FABP5 4631/4885FABP7 4721/4885 |
| US-20230026641-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND COMPRISING HIGHLY STERICALLY HINDERED AMINO ACID | DNPEP, VIP, NPEPPS | KMT2A 2469/4885FABP5 3048/4885FABP7 2102/4885 |
| US-20250186542-A1 | COMPOSITION CONTAINING PEPTIDE COMPOUND FOR USE WITH SURFACTANT | PCTP, CETP, PLTP | KMT2A 4643/4885FABP5 710/4885FABP7 529/4885 |
| US-12404299-B2 | Method for producing peptide compound comprising highly sterically hindered amino acid | DNPEP, VIP, NPEPPS | KMT2A 2469/4885FABP5 3048/4885FABP7 2102/4885 |
| US-20250353875-A1 | PEPTIDE SYNTHESIS METHOD FOR SUPPRESSING DEFECT CAUSED BY DIKETOPIPERAZINE FORMATION | VIP, NPPA, DNPEP | KMT2A 2092/4885FABP5 3537/4885FABP7 3487/4885 |
| US-20250230193-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | KRAS, HRAS, NRAS | KMT2A 1250/4885FABP5 4631/4885FABP7 4721/4885 |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | KRAS, NRAS, HRAS | KMT2A 3145/4885FABP5 4094/4885FABP7 4602/4885 |
| US-20250332300-A1 | HER2 TARGETING CYCLIC PEPTIDES AND CONJUGATES THEREOF | ERBB2, EGFR, ERBB3 | KMT2A 3524/4885FABP5 2094/4885FABP7 1269/4885 |
| US-20250302912-A1 | COMPOSITION INCLUDING PEPTIDE COMPOUND AND SURFACTANT | PCTP, CETP, PLTP | KMT2A 4487/4885FABP5 265/4885FABP7 645/4885 |
| US-20230096766-A1 | AMINO ACID HAVING FUNCTIONAL GROUP CAPABLE OF INTERMOLECULAR HYDROGEN BONDING, PEPTIDE COMPOUND CONTAINING SAME AND METHOD FOR PRODUCTION THEREOF | VIP, DNPEP, HM13 | KMT2A 3453/4885FABP5 1090/4885FABP7 572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.